The European Medicines Agency's Committee for Veterinary Medicinal Products has confirmed in a short bulletin that the long-anticipated guidance document on geroscience submissions will be published before the close of the current quarter. The confirmation was modest — a single line in a regular committee update — but it ends roughly eighteen months of speculation about whether and when Europe would catch up to the pathway the U.S. FDA-CVM has already opened.

The document is expected to address three areas that have been holding sponsors back. First, it will clarify which functional and biomarker endpoints the agency considers acceptable substitutes for survival data in initial submissions. Second, it will set out expectations for post-marketing surveillance specifically tailored to chronic-use medications in dogs, which is structurally different from the existing acute-treatment framework. Third, it will describe how member-state authorities will harmonize prescribing controls so that a dog under longevity therapy in one country isn't cut off when its owner relocates to another.

Industry sources have signalled that several programmes were waiting for exactly this guidance before deciding whether to file in Europe in 2026 or push their European submission to 2027. With the document now confirmed, at least two of the leading sponsors are expected to fast-track their European regulatory teams.

For owners in the EU, the practical timeline still depends on individual sponsors filing — a guidance document is the rulebook, not the approval. The realistic window for a first European prescription remains late 2026 at the earliest, and that's only if the first filing is submitted within ninety days of the guidance going public.

We'll mirror the document on the regulatory-status page within twenty-four hours of publication, with a plain-English summary of what each section actually means for an EU-based owner.